 |
|
Systematic Overview of Warfarin and Its Drug and Food Interactions
Anne M. Holbrook, MD, PharmD, MSc, FRCPC;
Jennifer A. Pereira, MSc;
Renee Labiris, PhD;
Heather McDonald, MSc;
James D. Douketis, MD, FRCPC;
Mark Crowther, MD, MSc, FRCPC;
Philip S. Wells, MD, FRCPC
Arch Intern Med. 2005;165:1095-1106.
ABSTRACT
Background Warfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions.
Data Sources MEDLINE, TOXLINE, IPA, and EMBASE databases from October 1993 to March 2004. Database searches combined the keyword warfarin with drug interactions, herbal medicines, Chinese herbal drugs, and food-drug interactions.
Study Selection Eligible articles contained original reports of warfarin drug or food interactions in human subjects. Non-English articles were included if sufficient information could be abstracted.
Data Extraction Reports were rated independently by 2 investigators for interaction direction, clinical severity, and quality of evidence. Quality of evidence was based on previously validated causation criteria and study design.
Data Synthesis Of 642 citations retrieved, 181 eligible articles contained original reports on 120 drugs or foods. Inter-rater agreement was excellent, with weighted  values of 0.84 to 1.00. Of all reports, 72% described a potentiation of warfarin’s effect and 84% were of poor quality, 86% of which were single case reports. The 31 incidents of clinically significant bleeding were all single case reports. Newly reported interactions included celecoxib, rofecoxib, and herbal substances, such as green tea and danshen.
Conclusions The number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, suggests that coadministration with warfarin should be avoided or closely monitored. More systematic study of warfarin drug interactions in patients is urgently needed.
INTRODUCTION
Warfarin is the most commonly used oral anticoagulant in North America and has established efficacy for the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease.1-4 The drug is a racemic mixture of 2 optically active isomers, though the S-enantiomer is approximately 5 times more potent than the R-enantiomer. Warfarin exerts its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX, and X.5 Both effectiveness and safety (primarily risk of bleeding) are related to blood international normalized ratio (INR) values. Monitoring of INR and dose adjustments of warfarin are frequently required, influenced by changes in concomitant medications, diet, alcohol consumption, acute illness, liver disease, and unknown factors.5
Despite the frequency and importance of warfarin’s drug and food interactions, the first systematic overview on the topic did not appear until 1994.6 For that review, we developed an interaction assessment tool that combined a "levels of evidence" approach with causation criteria, subject outcome, and proposed mechanisms. Although many drugs, including antibiotics, drugs affecting the central nervous system, and cardiac medications, had been reported to interact with warfarin, the quality of reports was so poor that few clinical recommendations could be made other than careful monitoring around initiating and discontinuing treatment with other medications. In the decade since that review, awareness and investigation of drug interactions and quality of evidence have grown, leading to the hypothesis that the number and quality of drug and food interactions would increase as well. We therefore performed a systematic overview of the literature, updating the evidence on warfarin drug and food interactions.
METHODS
Relevant literature was identified by searching MEDLINE, TOXLINE, IPA, EMBASE databases, Health Canada and Food and Drug Administration Web sites and personal files from October 1993 to the end of March 2004. The MeSH headings and keywords used for the search were warfarin and drug interactions. Non-English articles were included if they included an English abstract with sufficient information. To retrieve warfarin-herbal drug interactions and warfarin-food interactions, 2 additional searches were conducted using the MeSH headings and keywords warfarin and herbal medicines or Chinese herbal drugs, and MeSH headings food-drug interactions and warfarin, limited to English only. The bibliographies of the retrieved articles were checked for any additional pertinent studies. Articles were considered eligible for evaluation if they contained original data involving drug or food interactions with warfarin in human subjects. Interacting drugs had to be available in the United States or Canada. Eligible studies were evaluated independently by 2 authors according to the following 4 main categories.
SUBJECT
Subjects were classified as patients or healthy volunteers. Patients were then further stratified into 2 categories: volunteers and nonvolunteers. The former group were defined as patients requiring warfarin therapy who were prospectively entered into a study, whereas the latter group was exposed to the interacting drug during the course of usual warfarin therapy. Healthy volunteers were healthy individuals not requiring warfarin therapy.
INTERACTION CLASSIFICATION AND SEVERITY
The drug affected and the type of interaction (potentiation, inhibition, or no effect) were noted. Interactions that potentiated or inhibited the effect of warfarin were further rated as major, moderate, minor, or nonclinical.
Major potentiation was defined by death, major bleeding, or necessity to stop warfarin therapy entirely. Major bleeding episodes included those that were life-threatening as well as those that led to the loss of at least 2 units of blood in 7 days or less.7 Moderate potentiation meant that (1) there was an INR change requiring an adjustment in warfarin dosage or (2) the INR increased to greater than 5.0 or (3) there was an increase in INR by greater than 1.5. Minor potentiation interactions were defined as an INR increase in which (1) no change in warfarin dosage was required and (2) the ratio remained less than 5 and (3) the increase was less than 1.5. Potentiation interactions were classified as nonclinical if the only evidence of warfarin augmentation was a statistically significant increase in warfarin levels without change in INR or clinical status.
Major inhibition interactions were defined by the occurrence of thrombosis. Moderate inhibition (clinically relevant but less than major) indicated (1) a change in INR requiring an adjustment in warfarin dosage or (2) an INR decrease to less than 1.5 or (3) a decrease in INR by greater than 1.5 units. Minor inhibition interactions were defined by (1) an INR decrease requiring no change in warfarin dosage and (2) an INR decrease to a ratio that remained more than 1.5 and (3) a decrease in INR by less than 1.5. Inhibition interactions were classified as nonclinical if the only evidence of warfarin inhibition was a statistically significant decrease in warfarin levels.
An interaction was defined as having no effect if the interacting drug neither potentiated nor inhibited warfarin’s effect in any way described herein.
QUALITY OF STUDY
Reports were classified into 1 of 4 categories based on the quality of study design. As shown in Table 1, randomized controlled trials (RCTs) were subdivided into fair to excellent quality, with those involving more than 100 subjects arbitrarily given the highest rating. Poor quality reports included nonrandomized study designs, observational studies, pharmacokinetic studies, and case reports.
|
|
|
|
Table 1. Quality of Study Design
|
|
|
CAUSATION CRITERIA
For each report, the probability of the proposed interaction was rated from level I (highly probable) to level IV (highly improbable). Definitive evidence of an interaction required a level I causation rating from both healthy volunteer and patient-based reports in which both described identical interaction direction and severity. Level designation was based on how the article fulfilled 7 standard causation criteria.
- Is the timing correct for an interaction to be pharmacologically plausible?
In patient-based studies, warfarin must have been taken at a stabilized dose common to usual practice and prior to initiation of the interacting drug or food. For volunteer-based studies, subjects had to have received warfarin, both alone as well as with the interacting drug. In addition, we required that the potentially interacting drug had to be consumed (1) long enough to attain a significant plasma level and (2) in doses common to usual practice.
- Do laboratory tests (eg, international normalized ratio/prothrombin time/thrombotest) support the contention of an interaction?
In patient-based articles, the post-coadministration coagulation variable had to be out of therapeutic range, whereas for volunteer studies, a 20% change in coagulation parameters for volunteer studies was required. For articles concluding "no interaction," the absence of a statistically significant change in coagulation variables was required.
- Are other potential factors affecting warfarin pharmacokinetics/pharmacodynamics ruled out satisfactorily?
Factors such as diet, other medications, as well as certain medical conditions (hepatic dysfunction and hyperthyroidism) had to have been declared to be ruled out as possible causes of the outcome.
- Has the patient had a similar result with previous exposure to the same drug?
The patient had to have been taking the interacting drug in addition to warfarin at a time prior to that reported with a similar outcome.
- Was a dose-response relationship demonstrated for the interacting drug?
The alterations in the dose of the implicated interacting drug or food being administered with warfarin correlated with subsequent changes in coagulation variables, inferring a dose-response relationship.
- Was the subject rechallenged and, if so, did a similar response occur?
The interacting drug had to have been administered simultaneously with warfarin in 2 or more separate courses (the second course conducted to confirm the results of the first), with similar results each time.
- Are the authors’ conclusions supported by other objective evidence?
Other objective evidence such as plasma levels of warfarin or coagulation factors supported the authors’ conclusions.
RELIABILITY AND VALIDITY
The criteria and rating scheme were evaluated and approved a priori by a panel of experts in the fields of thromboembolism, clinical pharmacology, and clinical epidemiology to assure face validity. Interrater agreement for interaction direction and severity, quality of study, and level of causation was assessed using a weighted statistic.8
CONFLICTING EVIDENCE
If ratings differed among articles for the same interacting drug or food, a hierarchy was implemented (type of subject > quality of study > level of causation > severity of clinical outcome). For example, a case report involving a patient was considered to be superior to an RCT using healthy volunteers as subjects. If 2 or more articles had the same subject type, the result of the highest quality study was listed—a patient-based RCT was considered superior to a patient case report. If 2 or more articles with the same subject type and quality of study varied in level of causation and clinical outcome, the clinical outcome associated with the highest level of evidence was listed. For example, the case report describing moderate potentiation of warfarin by celecoxib, with a level II causation rating9 outweighed the level III case report describing a similar interaction.10 For 2 level III causation patient case reports describing amoxicillin’s effect on warfarin, the report describing major potentiation11 outweighed the one describing moderate potentiation.11
RESULTS
A total of 642 citations were identified, of which 205 contained original data on drug or food interactions with warfarin. Of these 205 articles, 181 were retrievable and available for review. The reviewed articles contained 187 separate reports of interactions involving 120 drugs or foods. The weighted statistic for the interaction direction and severity rating, level of causation evaluation, and quality of study rating among the reviewers were 0.98, 0.84, and 1.0 respectively. All rating disagreements were resolved by repeated review and consensus.
No study met our definition of excellent quality. Thirty-three small RCTs were rated fair or good quality, of which 28 involved healthy subjects and 26 concluded a lack of interaction between warfarin and the drug or food studied. Olestra,12 vitamin E,13 clopidogrel,14 coenzyme Q10/ginkgo biloba 10,15 and ciprofloxacin16 were the only drugs for which patient-based RCTs were conducted, with a "no effect" conclusion for olestra, vitamin E, clopidogrel, and coenzyme Q10/gingko biloba and nonclinical potentiation for ciprofloxacin. Of the reviewed studies, 148 (82%) were rated poor quality and 130 (88%) of these were case reports, of which 125 (96%) were single case reports.
Forty-one new reports were rated as level I causation (highly probable) for an interaction, with 14 reporting potentiation (acetaminophen,17 boldo-fenugreek,18 ciprofloxacin,16 citalopram,19 diltiazem,20 entacapone,21 fenofibrate,22 fish oil,23 mango,24 miconazole vaginal suppositories,25 quilinggao,26 sertraline,27 voriconazole,28 and zileuton29), 5 reporting inhibition (etodolac,30 mercaptopurine,31 mesalamine,32 ribavirin,33 and trazodone34), and 22 reporting "no effect" (anastrozole,35 argatroban,36 cilostazol,37 clopidogrel,14 donepezil hydrochloride,38 eprosartan,39 entacapone,40 gemifloxacin,41 levetiracetam,42 losartan,43 meloxicam,44 metrifonate,45 miglitol,46 modafinil,47 moexipril,48 montelukast,49 nateglinide,50 nefazodone,51 olestra,12 pantoprazole,52 sevelamer hydrochloride,53 and vitamin E13).
For 38 drugs or foods, level II causation (probable) criteria were met, and for the remaining 41 drugs or foods, the evidence was even less conclusive. Only 57 (31%) of the studies ruled out potential confounders, and fewer than 20% of the articles provided rechallenge data, demonstration of a dose response relationship, or a description of a previous exposure in which the patient experienced a similar effect.
Of all 184 reviewed reports, 128 (70%) described a potentiation of warfarin’s effect, while inhibition and "no effect" reports each comprised 28 (15%). There were 34 reports of a major interaction—3 case reports of thrombosis associated with trazodone, sulfasalazine, and propofol and 31 case reports describing a major potentiation. These included 8 deaths, 4 of which were due to intracranial bleeding associated with celecoxib, ciprofloxacin, and fluoxetine/diazepam coadministration.54-56 Only 2 of all 34 reports were level I, describing inhibition involving mesalamine and trazodone.32, 34 Several herbal drugs, foods rich in vitamin K, and carbamazepine were reported to decrease warfarin’s effect as were other anti-infective agents, including griseofulvin, rifampin, and penicillinase-resistant penicillins, such as nafcillin, dicloxacillin, and cloxacillin.
There were 3 drugs—terbinafine, ritonavir, and influenza vaccine—for which conflicting evidence of an interaction with warfarin was presented.57-63 A cumulative summary, combining evaluations from our original review6 with those of the update is presented in Table 2. Although few interactions met level I causation requirements, the recurrent reports on nonsteroidal anti-inflammatory drugs (NSAIDs),230 antibiotics (particularly macrolides—azithromycin,124 erythromycin,11 and clarithromycin126), azoles (fluconazole231 and miconazole25), amoxicillin, and quinolones (ciprofloxacin16 and levofloxacin139) continue. New alerts regarding the potential for major bleeding when warfarin is taken with cyclooxygenase-2 (COX-2) selective NSAIDs9-10,55, 232 or herbal drugs are raised.127, 233 Table 3 presents a summary of all clinically significant potentiation and inhibition interactions with warfarin, based on drug family and level of causation.
|
|
|
|
Table 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction*
|
|
|
|
|
|
|
Table 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug Group
|
|
|
The most commonly cited mechanisms for interactions with warfarin involved stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or nonstereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway (green tea). However, most of the interactions reported have no documented mechanism.
COMMENT
This updated review indicates that the number of reports of interactions between warfarin and drugs or foods is increasing, reaffirming both the anticoagulant’s widespread use and its use with concomitant medications. Although the true mechanisms of drug interactions almost always remain unknown, there are several pharmacokinetic and pharmacodynamic factors that could influence warfarin’s effect. Cholestyramine is thought to reduce the gastrointestinal absorption of warfarin.97, 234 The more potent warfarin S-isomer is metabolized by cytochrome P-450 (CYP) 2C9. Many of the drugs identified as potentiating warfarin’s effect are known inhibitors of CYP 2C9, including amiodarone, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, and sertraline.235 Rifampin and secobarbital are both known inducers of CYP 2C9.93, 102 The R-isomer of warfarin is metabolized by CYP 1A2 and CYP 3A4, and quinolones16, 139 inhibit CYP 1A2, and macrolides11, 124, 126 inhibit CYP 3A4. The azoles (several reports involving metronidazole, fluconazole, trimethoprim-sulfamethoxazole, miconazole, and voriconazole25, 28, 79, 81-83,236) are also considered to inhibit CYP 1A2 or CYP 3A4. The pharmacodynamics of warfarin may be influenced by medications that affect either vitamin K or the coagulation factors.237 Sudden changes in dietary sources of vitamin K such as leafy greens or a supplemented diet followed by a change in warfarin’s effect are relatively easy to understand.106, 238-240 However, for several drugs, including cephalosporins, levothyroxine, and clofibrate, their supposed pharmacodynamic interactions with warfarin are very poorly understood.76, 214, 241
Although understanding a drug’s pharmacology helps predict its potential for interaction with warfarin, the translation of these predictions into clinical reality is far from certain. We also found no evidence that specific factors might identify patient subgroups most at risk of pharmacokinetic drug interactions. Regular monitoring of INR remains the best protection against major harm due to these pharmacokinetic and pharmacodynamic interactions.
The most difficult groups of drugs to deal with are those that potentiate bleeding on their own. The risk of bleeding is then greater when taken with warfarin, and INR monitoring is of no help. This is an issue with other anticoagulants (such as heparin), antiplatelet drugs (eg, acetylsalicylic acid, clopidogrel, dipyridamole, sulfinpyrazone, and ticlopidine) and all NSAIDs including COX-2 selective NSAIDs. All of these drugs should be avoided in combination with warfarin unless proven to provide benefit that outweighs the risk of bleeding—for example, for artificial heart valves.237 Contrary to the early theories of safety of COX-2 selective NSAIDs, we do not consider them safe in combination with warfarin. Both celecoxib (10 cases moderate9, 232 to major9-10) and rofecoxib (2 cases moderate9) are reported to potentiate anticoagulation. Acetaminophen, which is the analgesic of choice for patients using warfarin, has case reports17, 242 as well as a case-control study243 suggesting moderate potentiation (perhaps based on mild factor VII depletion17, 243), although findings from an RCT in healthy volunteers were negative.244
The paradox noted in our original review continues, in that higher-quality studies describe minor or no interaction, while clinically important potentiation or inhibition interactions all originate from poor-quality reports. The overall quality of the interaction literature remains extremely poor, precluding definitive recommendations regarding the safe coadministration or avoidance of specific drugs and foods in users of warfarin. Case reports may be alarming, but their rarity and the lack of a control group, a denominator of use, or often even basic descriptive details makes it impossible to gauge their true accuracy or rate of harm. Small RCTs of new drugs given with warfarin are increasingly common as a result of demands of regulators. These studies, which are invariably carried out with healthy young male volunteers, are too small to provide any assurance of lack of interaction and are likely not generalizable to the usual warfarin consumer—an elderly person with active medical conditions using several other medications. Only 5 of 34 RCTs evaluated in this review involved sample sizes from 24 to 43 patients.12-16 Poor-quality literature is not merely an aggravation to review. Twenty of the interaction reports received a level IV causation rating, implying that the interaction was highly improbable based on the lack of fulfillment of basic causation criteria.56, 213-229 The publication of such reports is potentially harmful itself because it may generate unwarranted concern and erroneously influence prescribing. We were surprised to find no analyses of linked, large administrative databases examining drug interactions with warfarin.
This review has several limitations. Our literature search did not solicit all unpublished adverse interactions reported to drug manufacturers or governments. However, both Health Canada’s Canadian Adverse Drug Reaction Monitoring Program and Food and Drug Administration’s MedWatch were solicited for cases. We also were unable to review all non-English publications. The handling of conflicting evidence, while sensible, could have led to a mistaken conclusion. Others may not agree with our multidimensional, hierarchical evaluation methods.
In the extreme, no drug can be deemed "safe" based on our summary chart because the absence of proof of a severe interaction does not mean proof of absence. Idiosyncratic reactions can always be expected. We therefore continue to recommend careful monitoring of warfarin therapy at the time of introduction of any new medication, herbal product, or food. Herbal products are particularly problematic given the lack of quality control on their contents and the failure of clinicians to ask about their use.245-246
How can clinicians use this information? To prescribe safely, there are 3 choices: one is to never prescribe or allow another medicine to be given with warfarin. This is clearly impractical for most patients requiring warfarin. The second is to use an electronic medical record or prescribing system that will evaluate interactions among the patient’s entire profile of therapies.247-248 Because these systems are not available to most physicians and are frequently incomplete and sometimes inaccurate, a third approach is required. The third option is to group the majority of offending interacting drugs into easier-to-remember families or therapeutic groups, as we have done in Table 3. We recommend to exercise caution when adding any antibiotic to warfarin therapy, especially for macrolides, quinolones, and "azoles." Many common cardiovascular drugs, including statins, fibrates, heparin, aspirin, and amiodarone, are problematic. Also, NSAIDs, including COX-2 selective NSAIDs, should be avoided, as should omeprazole, alcohol, chloral hydrate, anabolic steroids, and a wide variety of, if not all, herbal supplements. New oral anticoagulants may soon be available but have not demonstrated superior long-term efficacy, safety, or drug interaction profile compared with warfarin.
CONCLUSIONS
In summary, there is an abundance of medications and foods for which an adverse interaction with warfarin, generally potentiation of warfarin’s effect, has been reported. While the drug interaction literature is generally of poor quality, relatively consistent reporting of interactions between warfarin and certain commonly used drugs and drug families (mainly anti-infective agents, lipid-lowering drugs, NSAIDs including COX-2 selective NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine) is cause for concern. In patients who are starting therapy with one of these medicines, consideration should be given to using an alternative medication with less potential for warfarin interactions (eg, rabeprazole instead of omeprazole and acetaminophen instead of NSAIDs). More frequent INR testing during the 2 weeks of the onset or discontinuation of treatment with other medications is advisable. Finally, we recommend the use of more rigorous methods to examine warfarin interactions in patients (eg, RCTs, N of 1 crossover studies, or large health database analyses).
AUTHOR INFORMATION
Correspondence: Anne M. Holbrook, MD, PharmD, MSc, FRCPC, Division of Clinical Pharmacology, McMaster University, c/o Centre for Evaluation of Medicines, 105 Main St E, Level P1, Hamilton, Ontario, Canada L8N 1G6 (holbrook{at}mcmaster.ca).
Accepted for Publication: December 21, 2004.
Financial Disclosure: None.
Author Affiliations: Centre for Evaluation of Medicines, St Joseph’s Healthcare, Hamilton, Ontario (Drs Holbrook and Labiris and Ms Pereira); Department of Medicine, McMaster University, Hamilton (Drs Holbrook, Labiris, Douketis, and Crowther); Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario (Dr Holbrook and Ms Pereira); Axon Clinical Research, Toronto (Ms McDonald) and Ottawa Civic Hospital Research Centre, Ottawa, Ontario (Dr Wells).
REFERENCES
1. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(suppl):194S-206S.
FREE FULL TEXT
2. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(suppl):220S-227S. [published correction appears in Chest. 2001;120:1044].
3. Hyers TMAG, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(suppl):176S-193S.
FREE FULL TEXT
4. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest. 2001;119(suppl):228S-252S. [published correction appears in Chest. 2001;120:1427].
FREE FULL TEXT
5. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. Chest. 2001;119(suppl 1):8S-21S.
FREE FULL TEXT
6. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683.
FREE FULL TEXT
7. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
8. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1981:212-225.
9. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm. 2001;58:2076-2080.
FREE FULL TEXT
10. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother. 2000;34:325-327.
ABSTRACT
11. Wood GD, Deeble T. Warfarin: dangers with antibiotics. Dent Update. 1993;20:350-353.
PUBMED
12. Beckey NP, Korman LB, Parra D. Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy. Pharmacotherapy. 1999;19:1075-1079.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
13. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol. 1996;77:545-546.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
14. Lidell C, Svedberg LE, Lindell P, Bandh S, Job B, Wallentin L. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost. 2003;89:842-846.
WEB OF SCIENCE
| PUBMED
15. Engelsen J, Nielsen JD, Hansen KE. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial. Ugeskr Laeger. 2003;165:1868-1871.
PUBMED
16. Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis. 1996;22:251-256.
FREE FULL TEXT
17. Gebauer MG, Nyfort-Handsen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy. 2003;23:109-112.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Lambert J, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy. 2001;21:509-512.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
19. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1997;44:199-202.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
20. Stoysich AM, Lucas BD, Mohiuddin SM, Hilleman DE. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther. 1996;34:56-60.
WEB OF SCIENCE
| PUBMED
21. Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 2002;53:485-491.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
22. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Ann Pharmacother. 1998;32:765-768.
ABSTRACT
23. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38:50-53.
FREE FULL TEXT
24. Monterrey-Rodriguez J. Interaction between warfarin and mango fruit [letter]. Ann Pharmacother. 2002;36:940-941.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
25. Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy. 2000;20:98-99.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
26. Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother. 2003;37:836-838.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
27. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet. 1997;32(suppl 1):37-42.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56:24-29.
29. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet. 1995;29(suppl 2):67-76.
30. Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. Clin Pharmacol Ther. 1994;55:305-316.
WEB OF SCIENCE
| PUBMED
31. Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy. 2003;23:260-264.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Marinella MA. Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother. 1998;32:841-842.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
33. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002;36:72-74.
ABSTRACT
34. Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother. 2000;34:734-736.
ABSTRACT
35. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001;51:429-435.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm. 2002;59:2078-2083.
FREE FULL TEXT
37. Mallikaarjun S, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet. 1999;37(suppl 2):79-86.
38. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol. 1998;46(suppl 1):45-50.
39. Kazierad DJ, Martin DE, Ilson B, et al. Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol. 1998;38:649-653.
ABSTRACT
40. Faaij RA, Burggraaf J, Schoemaker RC, van Amsterdam RGM, Cohen AF. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol. 2002;54:304-308.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
41. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy. 1999;45:491-495.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
42. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55-63.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
43. Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1995;35:1008-1015.
ABSTRACT
44. Turck D, Su CA, Heinzel G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol. 1997;51:421-425.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
45. Heinig R, Kitchin N, Rolan P. Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. Clin Drug Invest. 1999;18:151-159.
FULL TEXT
46. Schall R, Muller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung. 1996;46:41-46.
PUBMED
47. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42:205-214.
ABSTRACT
48. Van Hecken A, Verbesselt R, Depre M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol. 1993;45:291-293.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
49. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999;39:495-500.
ABSTRACT
50. Anderson DM, Shelley S, Crick N, Buraglio M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42:1358-1365.
ABSTRACT
51. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol. 1995;35:730-738.
ABSTRACT
52. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39:700-703.
WEB OF SCIENCE
| PUBMED
53. Burke S, Amin N, Incerti C, Plone M, Watson N. Sevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol. 2001;41:193-198.
ABSTRACT
54. Byrd DC, Gaskins SE, Parrish AM, Freeman LB. Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract. 1999;12:486-488.
PUBMED
55. McMorran M, Morawiecka I. Celecoxib (Celebrex): 1 year later. CMAJ. 2000;162:1044-1046, 1048-1050.
56. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997;17:170-172.
WEB OF SCIENCE
| PUBMED
57. Guerret M, Francheteau P, Huber M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy. 1997;17:767-773.
WEB OF SCIENCE
| PUBMED
58. Warwick JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. BMJ. 1998;316:440.
FREE FULL TEXT
59. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology. 1998;196:266-267.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
60. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS. 1999;13:1788-1789.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
61. Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis. 2002;13:297-300.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
62. Lipsky BA, Pecoraro RE, Roben NJ, de Blaquiere P, Delaney CJ. Influenza vaccination and warfarin anticoagulation. Ann Intern Med. 1984;100:835-837.
63. Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther. 1984;35:416-418.
WEB OF SCIENCE
| PUBMED
64. Duursema L, Muller FO, Hundt HK, Heyns AD, Meyer BH, Luus HG. Model to detect warfarin-drug interactions in man. Drug Investig. 1992;4:395-402.
65. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51:398-407.
WEB OF SCIENCE
| PUBMED
66. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol. 1985;28:257-261.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
67. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther. 1987;42:290-294.
WEB OF SCIENCE
| PUBMED
68. Pyorala K, Myllyla G, Kekki M. Metabolism of warfarin during methandrostenolone treatment. Ann Med Exp Biol Fenn. 1965;43:95-97.
WEB OF SCIENCE
| PUBMED
69. Lorentz SM, Weibert RT. Potentiation of warfarin anticoagulation by topical testosterone ointment. Clin Pharm. 1985;4:332-334.
WEB OF SCIENCE
| PUBMED
70. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32:165-172.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
71. O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144:989-991.
FREE FULL TEXT
72. Bell WR, Anderson KC, Noe DA, Silver BA. Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med. 1986;146:2325-2328.
FREE FULL TEXT
73. Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2:317-319.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
74. Sax MJ, Randolph WC, Peace KE, et al. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy. Clin Pharm. 1987;6:492-495. [published correction appears in Clin Pharm. 1988;7:269].
WEB OF SCIENCE
| PUBMED
75. Hunt BA, Sax MJ, Chretien S, Frank WO, Braverman AJ. Stereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens. Pharmacotherapy. 1989;9:184.
76. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh. 1972;27:309-318.
WEB OF SCIENCE
| PUBMED
77. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med. 1979;91:34-36.
78. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm. 1989;8:210-214.
WEB OF SCIENCE
| PUBMED
79. Black D, Evans J, Seaton T, Gidal B, McDonnell N, Kunze K. Evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]. Clin Pharmacol Ther. 1992;51:piii-52.
80. Rosenthal AR, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin. JAMA. 1977;238:2177.
FREE FULL TEXT
81. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976;295:354-357.
WEB OF SCIENCE
| PUBMED
82. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther. 1992;51:656-667.
WEB OF SCIENCE
| PUBMED
83. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11:176-184.
WEB OF SCIENCE
| PUBMED
84. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967;276:496-501.
85. O'Reilly RA, Trager WF, Motley CH, Howald W. Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest. 1980;65:746-753.
86. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm. 1985;19:556-558.
ABSTRACT
87. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther. 1987;42:305-311.
WEB OF SCIENCE
| PUBMED
88. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984;17(suppl 1):86S.
89. Bax ND, Lennard MS, Tucker GT, et al. The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 1984;17(suppl 1):85S.
90. Nenci GG, Agnelli G, Berrettini M. Biphasic sulphinpyrazone-warfarin interaction. Br Med J (Clin Res Ed). 1981;282:1361-1362.
91. O'Reilly RA. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation. 1982;65:202-207.
FREE FULL TEXT
92. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986;39:15-24.
WEB OF SCIENCE
| PUBMED
93. O'Reilly RA, Trager WF, Motley CH, Howald W. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther. 1980;28:187-195.
WEB OF SCIENCE
| PUBMED
94. Orme M, Breckenridge A. Enantiomers of warfarin and phenobarbital. N Engl J Med. 1976;295:1482-1483.
95. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther. 1971;12:539-543.
WEB OF SCIENCE
| PUBMED
96. Breckenridge A, Orme M. Clinical implications of enzyme induction. Ann N Y Acad Sci. 1971;179:421-430.
WEB OF SCIENCE
| PUBMED
97. Robinson DS, Benjamin DM, McCormack JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971;12:491-495.
WEB OF SCIENCE
| PUBMED
98. Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol. 1978;5:437-440.
WEB OF SCIENCE
| PUBMED
99. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm. 1986;20:291-293.
ABSTRACT
100. Cullen SI, Catalano P. Griseofulvin-warfarin antagonism. JAMA. 1967;199:582-583.
FREE FULL TEXT
101. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. Ann Intern Med. 1984;100:527-529.
102. O'Reilly RA. Interaction of sodium warfarin and rifampin: studies in man. Ann Intern Med. 1974;81:337-340.
103. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther. 1987;42:388-394.
WEB OF SCIENCE
| PUBMED
104. Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin [letter]. Ann Intern Med. 1983;98:557.
105. Talbert RL, Dalmady-Israel C, Bussey HI, Crawford MH, Ludden TM. Effect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy. Drug Intell Clin Pharm. 1985;19:59.
106. Qureshi GD, Reinders TP, Swint JJ, Slate MB. Acquired warfarin resistance and weight-reducing diet. Arch Intern Med. 1981;141:507-509.
FREE FULL TEXT
107. Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. Clin Pharm. 1982;1:274-276.
PUBMED
108. Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado [letter]. Lancet. 1991;337:914-915.
WEB OF SCIENCE
| PUBMED
109. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med. 1981;141:458-459.
FREE FULL TEXT
110. O'Reilly RA. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sci. 1979;277:189-194.
WEB OF SCIENCE
| PUBMED
111. Nipper H, Kirby S, Iber FL. Effect of bumetanide on the serum disappearance of warfarin sodium. J Clin Pharmacol. 1981;21:654-656.
ABSTRACT
112. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. Clin Pharmacol Ther. 1980;28:493-498.
WEB OF SCIENCE
| PUBMED
113. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther. 1987;42:33-41.
WEB OF SCIENCE
| PUBMED
114. De Lepeleire I, Van Hecken A, Verbesselt R, et al. Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res. 1990;10:167-171.
WEB OF SCIENCE
| PUBMED
115. Grind M, Murphy M, Warrington S, Aberg J. Method for studying drug-warfarin interactions. Clin Pharmacol Ther. 1993;54:381-387.
WEB OF SCIENCE
| PUBMED
116. Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci. 1978;23:807-812.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
117. Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1990;30:743-750.
WEB OF SCIENCE
| PUBMED
118. Benedek IH, King SY, Powell RJ, Agra AM, Schary WL, Pieniaszek HJ Jr. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1992;32:558-563.
FREE FULL TEXT
119. Jain A, McMahon FG, Slattery JT, Levy G. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther. 1979;25:61-66.
WEB OF SCIENCE
| PUBMED
120. Cournot A, Berlin I, Sallord JC, Singlas E. Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol. 1988;28:1120-1122.
ABSTRACT
121. Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12:791-794.
WEB OF SCIENCE
| PUBMED
122. Orme M, Breckenridge A, Cook P. Warfarin and distalgesic interaction. BMJ. 1976;1:200.
123. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother. 2003;37:367-370.
FREE FULL TEXT
124. Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19:902-908.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
125. Udall JA. Warfarin interactions with chloral hydrate and glutethimide. Curr Ther Res Clin Exp. 1975;17:67-74.
WEB OF SCIENCE
| PUBMED
126. Byers M. Clarithromycin-warfarin interaction resulting in an elevated INR. Can J Hosp Pharm. 1997;50:285-287.
127. Izzat MB, Yim AP, El Zufari MH. A taste of Chinese medicine. Ann Thorac Surg. 1998;66:941-942.
FREE FULL TEXT
128. Smith R, Prudden D, Hawkes C. Propoxyphene and warfarin interaction [letter]. Drug Intell Clin Pharm. 1984;18:822.
PUBMED
129. O'Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther. 1981;29:332-336.
WEB OF SCIENCE
| PUBMED
130. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999;19:870-876.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
131. Carabino J, Wang F. International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. Am J Health Syst Pharm. 2002;59:875.
FREE FULL TEXT
132. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
ABSTRACT
133. Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. Ann Pharmacother. 2002;36:1890-1892.
ABSTRACT
134. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. Pharmacotherapy. 1999;19:1331-1333.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
135. Bartle WR. Grapefruit juice might still be factor in warfarin response [letter]. Am J Health Syst Pharm. 1999;56:676.
WEB OF SCIENCE
| PUBMED
136. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. BMJ. 1995;311:292.
137. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. BMJ. 1990;301:669.
138. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother. 1994;28:464-467.
ABSTRACT
139. Ravnan SL, Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy. 2001;21:884-885.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
140. Lam AY, Elmer GW, Mohutsky MA. Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother. 2001;35:1199-1201.
ABSTRACT
141. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPES interact with warfarin? J Urol. 2002;167:1793.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
142. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin [letter]. Ann Oncol. 2003;14:500.
FREE FULL TEXT
143. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. Postgrad Med J. 1997;73:439-440.
FREE FULL TEXT
144. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm. 1984;3:200-203.
WEB OF SCIENCE
| PUBMED
145. Koch-Weser J. Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med. 1968;68:511-517.
146. Bair JD, Oppelt TF. Warfarin and ropinirole interaction. Ann Pharmacother. 2001;35:1202-1204.
ABSTRACT
147. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter]. Lancet. 1992;340:979-980.
WEB OF SCIENCE
| PUBMED
148. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:86-90.
ABSTRACT
149. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed). 1987;295:1141.
150. Westfall LK. An unrecognized cause of warfarin resistance [letter]. Drug Intell Clin Pharm. 1981;15:131.
PUBMED
151. Danos EA. Apparent potentiation of warfarin activity by tetracycline. Clin Pharm. 1992;11:806-808.
WEB OF SCIENCE
| PUBMED
152. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother. 1999;33:1173-1176.
ABSTRACT
153. Sabbe JR, Sims PJ, Sims MH. Tramadol-warfarin interaction. Pharmacotherapy. 1998;18:871-873.
WEB OF SCIENCE
| PUBMED
154. Scher ML, Huntington NH, Vitillo JA. Potential interaction between tramadol and warfarin [letter]. Ann Pharmacother. 1997;31:646-647.
WEB OF SCIENCE
| PUBMED
155. Plowman BK, Morreale AP. Possible troglitazone-warfarin interaction [letter]. Am J Health Syst Pharm. 1998;55:1071.
WEB OF SCIENCE
| PUBMED
156. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother. 2000;34:120-122.
WEB OF SCIENCE
| PUBMED
157. Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother. 2003;37:1028-1031.
FREE FULL TEXT
158. Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann A. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens. 1997;11(suppl 2):S31-S35.
159. Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy. 2002;22:1067-1069.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
160. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm. 1987;6:804-806.
WEB OF SCIENCE
| PUBMED
161. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. Ann Pharmacother. 1996;30:1402-1407.
ABSTRACT
162. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology. 2003;99:111.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
163. Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother. 2003;37:1603-1606.
FREE FULL TEXT
164. Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SRB. Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res. 2001;18:1024-1028.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
165. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998;32:1299-1302.
ABSTRACT
166. Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother. 2002;36:1893-1896.
ABSTRACT
167. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37:1062-1064.
ABSTRACT
168. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother. 2001;35:1535-1539.
ABSTRACT
169. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14:681-690.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
170. Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol. 1989;28:46-49.
FREE FULL TEXT
171. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21:151-158.
FREE FULL TEXT
172. Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol. 1993;44:205-206.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
173. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol. 2000;56:705-710.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
174. Morreale AP, Janetzky K. Probable interaction of warfarin and acarbose. Am J Health Syst Pharm. 1997;54:1551-1552.
FREE FULL TEXT
175. Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. West J Med. 1999;170:49-51.
WEB OF SCIENCE
| PUBMED
176. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:610-612.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
177. Malacarne P, Maestri A. Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter]. Recenti Prog Med. 1996;87:135.
PUBMED
178. Leone R, Ghiotto E, Conforti A, Velo G. Potential interaction between warfarin and ocular chloramphenicol [letter]. Ann Pharmacother. 1999;33:114.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
179. Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ. 2003;327:1454.
FREE FULL TEXT
180. Yue Q, Jansson K. Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter]. J Am Geriatr Soc. 2001;49:838.
WEB OF SCIENCE
| PUBMED
181. Booth CD. Drug interaction between danazol and warfarin. Pharm J. 1993;250:439-440.
182. Tam LS, Chan TY, Leung WK, Critchley JA. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter]. Aust N Z J Med. 1995;25:258.
WEB OF SCIENCE
| PUBMED
183. Sylven C, Anderson P. Evidence that disopyramide does not interact with warfarin. Br Med J (Clin Res Ed). 1983;286:1181.
184. Haworth E, Burroughs AK. Disopyramide and warfarin interaction. BMJ. 1977;2:866-867.
185. Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction: first report [letter]. Ann Pharmacother. 1994;28:805.
WEB OF SCIENCE
| PUBMED
186. Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S. Possible interaction between gatifloxacin and warfarin. Am J Health Syst Pharm. 2002;59:1205-1206.
FREE FULL TEXT
187. Rindone JP, Keng HC. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest. 1998;114:641-642.
FREE FULL TEXT
188. Chan TY, Lui SF, Chung SY, Luk S, Critchley JA. Adverse interaction between warfarin and indomethacin. Drug Saf. 1994;10:267-269.
WEB OF SCIENCE
| PUBMED
189. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgrad Med J. 1990;66:860-861.
FREE FULL TEXT
190. Ahmad S. Lovastatin: warfarin interaction. Arch Intern Med. 1990;150:2407.
FREE FULL TEXT
191. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ. 2002;325:1333.
FREE FULL TEXT
192. Trewin VF. A probable interaction between warfarin and metolazone. Pharm J. 1988;18:781-782.
193. Evans J, Orme DS, Sedgwick ML, Youngs GR. Treating oral candidiasis: potentially fatal [letter]. Br Dent J. 1997;182:452.
WEB OF SCIENCE
| PUBMED
194. Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin [letter]. Ann Intern Med. 1987;107:601.
195. Linville T, Matanin D. Norfloxacin and warfarin. Ann Intern Med. 1989;110:751-752.
196. Leor J, Matetzki S. Ofloxacin and warfarin [letter]. Ann Intern Med. 1988;109:761.
197. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin [letter]. Ann Intern Med. 1993;119:1223.
FREE FULL TEXT
198. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37:510-512.
FREE FULL TEXT
199. Littleton F. Warfarin and topical salicylates [letter]. JAMA. 1990;263:2888.
200. Chow WH, Cheung KL, Ling HM, See T. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med. 1989;82:501-502.
WEB OF SCIENCE
| PUBMED
201. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother. 1997;31:647.
WEB OF SCIENCE
| PUBMED
202. Carter SA. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants. Lancet. 1979;2:698-699.
WEB OF SCIENCE
| PUBMED
203. Ross JR, Beeley L. Sulindac prothrombin time and anticoagulants [letter]. Lancet. 1979;2:1075.
WEB OF SCIENCE
| PUBMED
204. Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit. 1995;17:33-38.
WEB OF SCIENCE
| PUBMED
205. Koren JF, Cochran DL, Janes RL. Tolmetin-warfarin interaction. Am J Med. 1987;82:1278-1280.
WEB OF SCIENCE
| PUBMED
206. Nissenblatt MJ, Karp GI. Bleeding risk with trastuzumab (Herceptin) treatment. JAMA. 1999;282:2299-2301.
FREE FULL TEXT
207. Snyder DS. Interaction between cyclosporine and warfarin [letter]. Ann Intern Med. 1988;108:311.
208. Ostlere LS, Langtry JA, Jones S, Staughton RC. Reduced therapeutic effect of warfarin caused by etretinate [letter]. Br J Dermatol. 1991;124:505.
WEB OF SCIENCE
| PUBMED
209. Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother. 2000;34:1265-1268.
ABSTRACT
210. Bartle WR, Madorin P, Guylaine F. Seaweed, vitamin K, and warfarin [letter]. Am J Health Syst Pharm. 2001;58:2300.
FREE FULL TEXT
211. Stangier J, Su CA, Hendriks MG, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol. 2000;40:1331-1337.
ABSTRACT
212. Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet. 1994;344:1372-1373.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
213. Beringer TR. Warfarin potentiation with bezafibrate. Postgrad Med J. 1997;73:657-658.
FREE FULL TEXT
214. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin. Ann Surg. 1987;206:155-161.
WEB OF SCIENCE
| PUBMED
215. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother. 1997;31:1006-1008.
ABSTRACT
216. Thomas P, Fennerty A, Blackhouse G. Oral anticoagulant during treatment with heparin. Br Med J (Clin Res Ed). 1984;288:191.
217. Wehbe TW, Warth JA. A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Clin Pharmacol Ther. 1996;59:360-362.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
218. Ellison J. Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ. 2000;321:1382.
FREE FULL TEXT
219. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler. 1997;3:248-249.
FREE FULL TEXT
220. Dennis VC, Thomas BK, Hanlon JE. Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. Pharmacotherapy. 2000;20:234-239.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
221. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine [letter]. J Clin Psychopharmacol. 1999;19:382-383.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
222. Sioris LJ, Weibert RT, Pentel PR. Potentiation of warfarin anticoagulation by sulfisoxazole. Arch Intern Med. 1980;140:546-547.
FREE FULL TEXT
223. Ibrahim OM, Allam A. Warfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin. Saudi Pharm J. 1996;4:56-59.
224. Laizure SC, Madlock L, Cyr M, Self T. Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Ther Drug Monit. 1997;19:361-363.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
225. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. 1999;33:426-428.
ABSTRACT
226. Setter SM, Lawless K, Hunter KA. Need for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin. Hosp Pharm. 1996;31:1269-1271.
227. MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy. 1997;17:1331-1337.
WEB OF SCIENCE
| PUBMED
228. Agosta FG, Liberato NL, Chiofalo F. Warfarin resistance induced by teicoplanin [letter]. Haematologica. 1997;82:637-638.
FREE FULL TEXT
229. May JR, DiPiro JT, Sisley JF. Drug interactions in surgical patients. Am J Surg. 1987;153:327-335.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
230. Gabb GM. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter]. Med J Aust. 1996;164:700-701.
WEB OF SCIENCE
| PUBMED
231. Baciewicz AM, Menke JJ, Bokar JA, Baud EB. Fluconazole-warfarin interaction [letter]. Ann Pharmacother. 1994;28:1111.
WEB OF SCIENCE
| PUBMED
232. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother. 2000;34:666-667.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
233. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997;54:692-693.
FREE FULL TEXT
234. Holbrook AM, Wells PS, Crowther NR. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J, eds. Oral Anticoagulants. Dunton Green, England: Hodder and Stoughton; 1996.
235. Indiana University Department of Medicine Web site. Cytochrome P450 drug interaction table. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed July 15, 2004.
236. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med. 1980;302:33-35.
WEB OF SCIENCE
| PUBMED
237. Hirsh J, Ansell J, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation. 2003;107:1692-1711.
FREE FULL TEXT
238. Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc. 1995;95:580-584.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
239. O'Reilly RA, Rytand D. "Resistance" to warfarin due to unrecognized vitamin K supplementation [letter]. N Engl J Med. 1980;303:160-161.
240. Pedersen FM, Hamburg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulants. J Intern Med. 1991;229:517-520.
WEB OF SCIENCE
| PUBMED
241. Owens JC, Neely JB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulation. N Engl J Med. 1962;266:76-79.
242. Antlitz AM, Mead JA Jr, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res Clin Exp. 1968;10:501-507.
WEB OF SCIENCE
| PUBMED
243. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-662.
FREE FULL TEXT
244. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:68-75.
ABSTRACT
245. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharm. 1998;23:80, 83-84, 86.
246. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal—part I. Prog Drug Res. 2001;56:1-76.
PUBMED
247. Holbrook AM, Janjusevic V, Keshavjee K, Lee HK. Measuring quality of prescribing: where does the information reside? [abstract]. Can J Clin Pharmacol. 2002;9:40.
248. Holbrook AM, Keshavjee K, Goldsmith CH, Tucker J, Park L. Advancing the measurement of quality of care using electronic medical records. Proc Towards Electron Patient Rec. 1999;1:848-855.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Comments on the Important Drug Interaction of Warfarin and Sulfamethoxazole
John Erwin Campbell and William H. Carter
Arch Intern Med. 2005;165(21):2540.
EXTRACT
| FULL TEXT
Comments on the Important Drug Interaction of Warfarin and Sulfamethoxazole—Reply
Anne Holbrook and Jennifer Pereira
Arch Intern Med. 2005;165(21):2540.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study
David G. Sherman, Soo G. Kim, Bradley S. Boop, Scott D. Corley, John P. DiMarco, Robert G. Hart, L. Julian Haywood, Keith Hoyte, Elizabeth S. Kaufman, Michael H. Kim, Elaine Nasco, Albert L. Waldo, and for the National Heart, Lung, and Blood Institute AFFIRM Investigators
Arch Intern Med. 2005;165(10):1185-1191.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Ageno et al.
Chest 2012;141:e44S-e88S.
ABSTRACT
| FULL TEXT
Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Holbrook et al.
Chest 2012;141:e152S-e184S.
ABSTRACT
| FULL TEXT
Probable Warfarin and Dapsone Interaction
Truong and Haley
CLIN APPL THROMB HEMOST 2012;18:107-109.
ABSTRACT
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding
Lopes and Garcia
Evid. Based Med. 2011;16:187-188.
FULL TEXT
Antithrombotic Therapy Use at Discharge and 1 Year in Patients With Atrial Fibrillation and Acute Stroke: Results From the AVAIL Registry
Lopes et al.
Stroke 2011;42:3477-3483.
ABSTRACT
| FULL TEXT
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Steffel and Braunwald
Eur Heart J 2011;32:1968-1976.
ABSTRACT
| FULL TEXT
Riociguat (BAY 63-2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study
Frey et al.
J Clin Pharmacol 2011;51:1051-1060.
ABSTRACT
| FULL TEXT
Intensity of Anticoagulation with Warfarin and Risk of Adverse Events in Patients Presenting to the Emergency Department
Anthony et al.
The Annals of Pharmacotherapy 2011;45:881-887.
ABSTRACT
| FULL TEXT
High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice
Guthrie et al.
BMJ 2011;342:d3514-d3514.
ABSTRACT
| FULL TEXT
Hemorrhagic and Thrombotic Events Associated with Generic Substitution of Warfarin in Patients with Atrial Fibrillation: A Retrospective Analysis
Ghate et al.
The Annals of Pharmacotherapy 2011;45:701-712.
ABSTRACT
| FULL TEXT
Critical issues associated with drug-drug interactions: Highlights of a multistakeholder conference
Hines et al.
Am J Health Syst Pharm 2011;68:941-946.
FULL TEXT
Assessing Evidence of Interaction Between Smoking and Warfarin: A Systematic Review and Meta-analysis
Nathisuwan et al.
Chest 2011;139:1130-1139.
ABSTRACT
| FULL TEXT
Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants
Bavisotto et al.
J Clin Pharmacol 2011;51:561-574.
ABSTRACT
| FULL TEXT
Probable interaction between warfarin and bee pollen
Hurren and Lewis
Am J Health Syst Pharm 2010;67:2034-2037.
ABSTRACT
| FULL TEXT
Perioperative Management of Chronic Anticoagulation in Orthopaedic Surgery
Thakur et al.
J Am Acad Orthop Surg 2010;18:729-738.
ABSTRACT
| FULL TEXT
Predisposing Preventable Factors in Patients With Bleeding due to Warfarin Usage: Evaluation of 114 Patients
Beyan et al.
CLIN APPL THROMB HEMOST 2010;16:684-687.
ABSTRACT
Patient Factors That Influence Warfarin Dose Response
White
Journal of Pharmacy Practice 2010;23:194-204.
ABSTRACT
An Evaluation of the Early Pharmacodynamic Response After Simultaneous Initiation of Warfarin and Amiodarone
Edwin et al.
J Clin Pharmacol 2010;50:693-698.
ABSTRACT
| FULL TEXT
Minimizing the Risks of Anticoagulants and Platelet Inhibitors
Alexander and Peterson
Circulation 2010;121:1960-1970.
FULL TEXT
Influenza Vaccination and Vitamin K Antagonist Treatment: A Placebo-Controlled, Randomized, Double-blind Crossover Study
Iorio et al.
Arch Intern Med 2010;170:609-616.
ABSTRACT
| FULL TEXT
Hemorrhage During Warfarin Therapy Associated With Cotrimoxazole and Other Urinary Tract Anti-infective Agents: A Population-Based Study
Fischer et al.
Arch Intern Med 2010;170:617-621.
ABSTRACT
| FULL TEXT
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Kirchhof et al.
Eur Heart J 2009;30:2969-2980.
ABSTRACT
| FULL TEXT
An algorithm for managing warfarin resistance
OSINBOWALE et al.
Cleveland Clinic Journal of Medicine 2009;76:724-730.
ABSTRACT
| FULL TEXT
Gastrointestinal Safety of Nonsteroidal Antiinflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Patients on Warfarin
Cheetham et al.
The Annals of Pharmacotherapy 2009;43:1765-1773.
ABSTRACT
| FULL TEXT
Comment: Fatal Intracranial Bleed Potentially Due to a Warfarin and Influenza Vaccine Interaction
Chock et al.
The Annals of Pharmacotherapy 2009;43:1913-1913.
FULL TEXT
The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Double-Blind Trial
Ansell et al.
J Clin Pharmacol 2009;49:824-830.
ABSTRACT
| FULL TEXT
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Kirchhof et al.
Europace 2009;11:860-885.
FULL TEXT
Prevalence of Use and the Risk of Adverse Effects Associated with Complementary and Alternative Medicine in a Cohort of Patients Receiving Warfarin
Leung et al.
The Annals of Pharmacotherapy 2009;43:875-881.
ABSTRACT
| FULL TEXT
Atrial Fibrillation: Pathogenesis, Medical-Surgical Management and Dental Implications
Friedlander et al.
Journal of the American Dental Association 2009;140:167-177.
ABSTRACT
| FULL TEXT
Interaction between statins and clopidogrel: is there anything clinically relevant?
Bhindi et al.
QJM 2008;101:915-925.
ABSTRACT
| FULL TEXT
Azathioprine-Induced Warfarin Resistance
Vazquez et al.
The Annals of Pharmacotherapy 2008;42:1118-1123.
ABSTRACT
| FULL TEXT
Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT
| FULL TEXT
Overanticoagulation with Coumarin and Cutaneous Azole Therapy
Alexandra et al.
ANN INTERN MED 2008;148:633-635.
FULL TEXT
Primary Prevention of Venous Thromboembolism in Long-Term Care: Identifying and Managing the Risk
Haas and Spyropoulos
CLIN APPL THROMB HEMOST 2008;14:149-158.
ABSTRACT
Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins
Schalekamp et al.
Arch Intern Med 2008;168:180-185.
ABSTRACT
| FULL TEXT
Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
Zielinska et al.
J. Pharmacol. Exp. Ther. 2008;324:139-148.
ABSTRACT
| FULL TEXT
Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients
Lenzini et al.
The Annals of Pharmacotherapy 2007;41:1798-1804.
ABSTRACT
| FULL TEXT
Interaction between lopinavir/ritonavir and warfarin
Hughes et al.
CMAJ 2007;177:357-359.
ABSTRACT
| FULL TEXT
Drug interactions with warfarin: what clinicians need to know
Juurlink
CMAJ 2007;177:369-371.
FULL TEXT
Potential drug-drug interactions within Veterans Affairs medical centers
Mahmood et al.
Am J Health Syst Pharm 2007;64:1500-1505.
ABSTRACT
| FULL TEXT
Best practice in primary care pathology: review 8
Smellie et al.
J. Clin. Pathol. 2007;60:740-748.
ABSTRACT
| FULL TEXT
Interaction potential between cranberry juice and warfarin
Pham and Pham
Am J Health Syst Pharm 2007;64:490-494.
ABSTRACT
| FULL TEXT
Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-Independent sGC Activator HMR1766
Oberwittler et al.
J Clin Pharmacol 2007;47:70-77.
ABSTRACT
| FULL TEXT
Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review.
Johnson et al.
Eur Respir J 2006;28:999-1004.
ABSTRACT
| FULL TEXT
Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin: Assessment of Incidence, Case-Fatality Rate, Time Course and Sites of Bleeding, and Risk Factors for Bleeding.
Douketis et al.
Arch Intern Med 2006;166:853-859.
ABSTRACT
| FULL TEXT
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
Gerber et al.
JCO 2006;24:1310-1318.
ABSTRACT
| FULL TEXT
Evidently ...
LEHMAN
Evid. Based Med. 2005;10:167-167.
FULL TEXT
Other articles noted
Evid. Based Med. 2005;10:191-192.
FULL TEXT
Comments on the Important Drug Interaction of Warfarin and Sulfamethoxazole
Campbell and Carter
Arch Intern Med 2005;165:2540-2540.
FULL TEXT
|
